The following is a roundup of coverage of MassBio’s release of the 2025 Biopharma Funding & Pipeline Report on Thursday, January 8, 2026.
‘A little bit more certainty’: After shaky years, Mass. life sciences companies find glimmers of hope (Marin Wolf in The Boston Globe)
MassBio chief executive Kendalle Burlin O’Connell dubbed 2025 the “year of the mega round,” where investors, turned off by the uncertainty of the market, put large amounts in only a few companies. That posed a challenge for Greater Boston’s biotech ecosystem, which specializes in early-stage startups that have only a few drug candidates.
“One of the things I’d like to see in 2026 as it relates to venture capital funding is what we would see back in 2018 and 2019,” Burlin O’Connell said. “I’d like to see more rounds spread amongst more companies, and lower dollar amounts.”
For all of the turmoil experienced by US life sciences companies, Massachusetts biotechs fared well by comparison, outpacing the overall growth rate of drug candidates among US companies by more than 7 percent, according to MassBio’s new report.
Read the full story at BostonGlobe.com.
Pulse check on U.S.’ biopharma hot spot (Fraiser Kansteiner for Fierce Biotech)
The report, published by local trade group MassBio, offers a snapshot of the industry in one of the nation’s premier biopharma hot spots.
Overall, the theme of the report was resilience, reflected in the fact that the state’s biopharma industry increased the volume of its drug pipeline by nearly 14% compared to 2024, even as venture capital reached its “lowest level in six years.”
Preclinical candidates made up the bulk of that gain, which outpaced the U.S.’ overall pipeline growth of 6.8% in 2025, according to the report.
Conversely, companies based in or with a significant presence in Massachusetts still rounded up 28 FDA approvals last year, MassBio noted. Throughout the course of 2025, the FDA approved 46 novel drugs and 18 new biological treatments, compared to 50 and 18 in 2024, respectively. Considering MassBio’s numbers, Massachusetts-based companies contributed significantly to that tally of U.S. nods.
Still, the trade group’s report came with a stark warning about the pace of innovation among U.S. rivals, with China’s pipeline growing a staggering 37% last year, by MassBio’s tally.
That being said, key barometers of the industry’s health—venture capital, M&A activity and initial public offerings from biotech upstarts—seem to be pointing in a more positive direction after a rough start to 2025.
Read the full story at FierceBiotech.com.
3 positive trends for Massachusetts’ biopharma sector (Michael Gibney in PharmaVoice)
Unveiling a recent report from MassBio that takes a look at the state’s biotech funding and innovation environment, CEO Kendalle Burlin O’Connell wrote, “Massachusetts built its leading biotech cluster by investing in breakthrough science at its earliest and riskiest stages … [and] American leadership in biotechnology is both a national security imperative and an economic priority.”
Here are three reasons from the report that point to potentially a brighter future for Massachusetts’ biotech despite recent hard times.
1 – Innovation expansion
Massachusetts drugmakers have stayed resilient in the face of a difficult financial landscape, and they have innovation growth to show for it. MassBio reported that biopharma companies in the state advanced their pipelines by almost 14% year over year in 2025, ahead of the U.S. growth of just 6.8%.Companies with Massachusetts headquarters made up more than 16% of the U.S. drug pipeline in 2025, up a percentage point from the year before. That puts the state at 6.4% of the global pipeline.
And a lot of that innovation was in much-needed early science with preclinical candidates comprising the “largest jump” in pipeline growth, according to MassBio.
Read the full story at PharmaVoice.com.
NIH funding cuts in Mass. totaled $125M in 2025, less than predicted (Hannah Baratham-Green in the Boston Business Journal)
Funding cuts to the National Institutes of Health sent fear through the biotech community in 2025. But new data shows the actual amount of federal funds Massachusetts lost were not as bad as was anticipated.
Last summer, MassBio predicted that the Bay State would end 2025 with a $500 million shortfall if NIH funding continued at the pace up to that point. But following a series of court rulings, policy changes, and grant awarding in September, the numbers ticked up in the latter half of 2025, according to the “2025 Massachusetts Biopharma Funding and Pipeline Report” put out by MassBio.
The life sciences trade group said NIH funding cuts ended up being around $125 million last year in Massachusetts, with additional funding data yet to be released.
Read the full story in the Boston Business Journal.
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026 (Tristan Manalac in BioSpace)
Money flowing into biopharma slowed to a trickle in 2025. But even as venture capital dropped to its lowest level in years, analysts have spotted hopeful signs, offering encouragement that funding could pick up in 2026.
Across Massachusetts—one of biopharma’s central hotspots—venture capital (VC) investment dropped to $6.85 billion in 2025, the lowest it has reached since 2019 when companies collectively scored $4.37 billion in VC funding, according to the 2025 funding and pipeline report of Massachusetts-focused trade group MassBio. For comparison, VC dollars pumped into the state equaled $7.89 billion in 2024.
“Reluctant private investors, a closed IPO window, cautious pharma, and layoffs [defined] the first half of the year,” the group wrote.
Things started picking up toward the end of 2025, however. Around 60% of all VC funding last year was announced in the back half of the year, which, according to MassBio, could be a sign of good tidings for the industry into 2026.
“Decreased interest rates and increasing clarity on pricing and tariffs enabled a stronger second half period,” a MassBio representative told BioSpace in an email. “A stronger second half of the year in VC funding and M&A [mergers & acquisitions] activity is a trend to watch for the new year,” the group added in a news release alongside its report.
Such an outlook tracks with similarly optimistic forecasts from other analysts. Leerink Partners was “generally sanguine” about biopharma’s prospects for fundraising this year as the industry continues to gain momentum and attract attention from generalist investors, the group said in a Dec. 17 report.
Read the full story at BioSpace.com.
Report: Biopharma uncertainty and instability bogged down 2025 (Alison Kuznitz for the State House News Service)
MassBio found Massachusetts-headquartered bipharma companies secured 26.2% of the industry’s U.S. venture dollars in 2025, compared to 28.3% in the year prior. Massachusetts trailed only California in 2025, which accounted for 43.3% of U.S. venture dollars.
The commonwealth’s share of venture dollars went to 187 companies in 2025, compared to 215 in the previous year, according to the report. Just over 70% of venture capital funding flowed to companies outside Cambridge, and Boston surpassed Cambridge’s funding for a second year in a row.
There were just two IPOs among Massachusetts biopharma companies in 2025, compared to six in the previous year. In 2021, MassBio had counted 25 IPOs.
Thirty-six Massachusetts companies were acquired in 2025 for a total of $20 billion. By contrast, in 2024, 32 companies were acquired at a total value of more than $42 billion, according to MassBio.
A dozen companies made acquisitions totaling $299 million in 2025, while 25 companies made acquisitions worth $10.62 billion in 2024, MassBio said.
The commonwealth’s pipeline of drug candidates increased by nearly 14% from 2024 to 2025, compared to the country’s overall increase of 6.8%. The most common therapeutic areas involved oncology, the central nervous system and anti-infectives. But China’s pipeline grew by 37%, the report pointed out.
“American leadership in biotechnology is both a national security imperative and an economic priority,” MassBio CEO Kendalle Burlin O’Connell said. “Massachusetts companies are building the drug pipeline that will define the next decade of cures and therapies, and MassBio will continue advocating for the federal investments and policy reforms that keep the United States competitive on the global stage.”